Zydus Cadila testing a multi-variant Covid-19 vaccine on animals



Ahmedabad-based Cadila Healthcare (Zydus Cadila), which has developed the first approved DNA vaccine in the world for Covid-19, is testing a multi-variant Covid-19 vaccine on animals, a senior company official said.


“We have completed our development for almost eight strains of the Sars-Cov-2 virus. We are now doing animal studies to see which of these constructs work the best to neutralise more mutations of Sars-CoV-2. It can be a vaccine construct using one strain or may be two strains,” said Sharvil Patel, MD,





Patel said the vaccine was in the product development stage and animal studies would show which combination was most effective. Tweaking the DNA-plasmid platform is relatively easy, and takes less time. All one needs to do is to change the sequence of the strains, and the whole construct of the vaccine, the whole model, and the process remain the same. “It is like plug-and-play technology, where all you have to do is to change the strain. We need not change anything that is part of the vaccine platform,” Patel said.


As such, Zydus Cadila’s ZyCoV-D, the DNA vaccine, when administered, induces production of spike protein of the Sars-CoV-2 virus. It is also stable across a wide temperature range. It is stable at 2 to 8 degrees and also at 25 degrees Celsius for around three months, unlike the stringent temperature requirement of mRNA vaccines.


Zydus has developed India’s first tetravalent influenza vaccine Vaxiflu-4, which offers protection against four influenza viruses — H1N1, H3N2, Type B (Brisbane), Type B (Phuket).


Mixing multiple strains to get what is called a multi-variant vaccine may be a way to get better immunity, scientists feel. Experts like Gagandeep Kang, microbiologist and professor at Christian Medical College, Vellore, pointed out that the scientific community feels that one needs to prepare for the future waves of the pandemic.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *